Innovent Biologics Inc., a leading biopharmaceutical company, has announced updated clinical data for IBI354, a novel anti-HER2 antibody-drug conjugate $(ADC)$, during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The data, derived from a Phase 1/2 clinical study, highlights the promising anti-tumor efficacy and favorable safety profile of IBI354 across various advanced solid tumors, including ovarian and breast cancer. This study included 368 participants and demonstrated no dose-limiting toxicities at doses up to 18mg/kg, with the most common treatment-related adverse events being anemia, nausea, and a decrease in white blood cell count. The incidence of interstitial lung disease was low at 1.9% and limited to grades 1-2. These findings support Innovent's ongoing development of next-generation ADC therapies and further clinical studies are planned, including a Phase 3 study in platinum-resistant ovarian cancer.